c19early.org COVID-19 treatment researchCOVID-19 treatments

Supplementary Data — Xiannuoxin for COVID-19: real-time meta-analysis of 2 studies

@CovidAnalysis, November 2026, Version 1V1

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

Xiannuoxin COVID-19 outcomes

c19early.org

November 2026

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Cao (DB RCT)17%0.83 · 0.74–0.94recov. time504 (n)503 (n) Wang (DB RCT)68%0.32 · 0.10–1.03recovery12 (n)8 (n) Wang (DB RCT)48%0.52 · 0.18–1.52recovery10 (n)8 (n) Wang (DB RCT)38%0.62 · 0.34–1.12viral load12 (n)8 (n) Wang (DB RCT)14%0.86 · 0.47–1.57viral load12 (n)8 (n)

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Xiannuoxin
reduces riskXiannuoxin
increases risk →

Fig. S1. All outcomes.

Most accessed treatments

Antiviral effects

Vitamins & Minerals

Host endosomal entry / trafficking

Dual-action mAbs

RdRp

Nasal & Oral Sprays / Rinses

Analgesics

Antiandrogens

Host targets and pathways

Inflammatory and immune modulation

Mpro (Gen 1)

Oxidative stress and cytoprotection

Lifestyles

TMPRSS2

Spike neutralization

Replication inhibition (target unresolved)

COVID-19 mAbs

Pleiotropic modulation

Attachment / entry inhibition

Mpro (Gen 2)

H1RAs

Nutrients and microbiome support

Host mAbs

IL-6 / IL-6R blockade

Physical and extracorporeal interventions

Natural products and extracts

Symptom management

Unconfirmed antiviral rationale

Lifestyle, behaviors, and exposure prevention

Other complication management

Mpro / 3CLpro

Host pyrimidine synthesis

Direct viral inactivation

Endothelial / vascular protection

Direct respiratory tract treatments

Other antibodies, proteins, peptides, cells, and RNA therapies

Secondary infection and coinfection management

Supplementary Data — Xiannuoxin for COVID-19: real-time meta-analysis of 2 studies

Xiannuoxin COVID-19 outcomes